einstein (São Paulo). 02/May/2019;17(2):eAO4583.

Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis

Marina Paula Andres ORCID logo , Renata Franco Pimentel Mendes ORCID logo , Camila Hernandes ORCID logo , Sérgio Eduardo Alonso Araújo ORCID logo , Sérgio Podgaec ORCID logo

DOI: 10.31744/einstein_journal/2019AO4583

ABSTRACT

Objective:

To evaluate clinical features and complications in patients with bowel endometriosis submitted to hormonal therapy.

Methods:

Retrospective study based on data extracted from medical records of 238 women with recto-sigmoid endometriosis treated between May 2010 and May 2016.

Results:

Over the course of follow-up, 143 (60.1%) women remained in medical treatment while 95 (39.9%) presented with worsening of pain symptoms or intestinal lesion growth (failure of medical treatment group), with surgical resection performed in 54 cases. Women in the Medical Treatment Group were older (40.5±5.1 years versus 37.3±5.8 years; p<0.0001) and had smaller recto sigmoid lesions (2.1±1.9 versus 3.1±2.2; p=0.008) compared to those who had failed to respond to medical treatment. Similar significant reduction in pain scores for dysmenorrhea, chronic pelvic pain, cyclic dyschezia and dysuria was observed in both groups; however greater reduction in pain scores for dyspareunia was noted in the Surgical Group. Subjective improvement in pain symptoms was also similar between groups (100% versus 98.2%; p=0.18). Major complications rates were higher in the Surgical Group (9.2% versus 0.6%; p=0.001).

Conclusion:

Patients with recto-sigmoid endometriosis who failed to respond to medical treatment were younger and had larger intestinal lesions. Hormonal therapy was equally efficient in improving pain symptoms other than dyspareunia compared to surgery, and was associated with lower complication rates in women with recto-sigmoid endometriosis. Medical treatment should be offered as a first-line therapy for patients with bowel endometriosis. Surgical treatment should be reserved for patients with pain symptoms unresponsive to hormonal therapy, lesion growth or suspected intestinal subocclusion.

Hormone treatment as first line therapy is safe and relieves pelvic pain in women with bowel endometriosis

Comments